The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...
EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME, with one phase 3 trial ongoing and one more planned for 2025. EYP-1901 demonstrated strong safety ...
A 4D Molecular Therapeutics, Inc. phase 2 PRISM study indicated that there was an 89% reduction in annualized injections when Wet-AMD patients were given a high dose of 4D-150; Phase 3 trial ...
Please provide your email address to receive an email when new articles are posted on . Improved tools are needed to collect real-world patient-reported outcomes in geographic atrophy. More data will ...
Hopes remain for Unity Biotechnology Inc.’s UBX-1325 in diabetic macular edema (DME) following a phase II miss in wet age-related macular degeneration (AMD), where data from part A of the study called ...
- DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 - - New ...
Patients with diabetic macular edema experienced visual acuity gains and reduced central subfield thickness after 2 years of treatment with Beovu, according to a press release from Novartis. Week 100 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback